Catalyst
Slingshot members are tracking this event:
Phase 2 updated data of Blueprint Medicines' (BPMC) Avapritinib BLU-285 - PIONEER trial in Indolent and smoldering systemic mastocytosis (SM) due at the AAAAI Annual Meeting March 14, 2020
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BPMC | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 16, 2020
Occurred Source:
http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-part-1-results-pioneer-trial
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Avapritinib, Blu-285, Smoldering Systemic Mastocytosis, Indolent Systemic Mastocytosis
